NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
199
NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected in 2H 2026, and multiple updates in 3Q and 4Q 2025 across psoriasis (SGX302) and Behçet’s Disease (SGX945). An investigator-initiated study also showed a 75% success rate at 18 weeks. The company projects HyBryte(TM) peak U.S. annual sales of over $90 million and global opportunities exceeding $2 billion across its pipeline. With approximately $7 million in cash and active exploration of partnerships and M&A, Soligenix aims to extend its cash runway into 1Q 2026 while preparing for global regulatory filings and potential commercialization.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

Soligenix Inc. (SNGX) Stock Research Links

SNGX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 19

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 22

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 16

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 9

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 13

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 21

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading

Top 5 Most Recently Viewed Articles

Niterra and Rackspace: Seamless Migration to Google Cloud

Updated Category News Views 126

Niterra and Rackspace: A Strategic Partnership for Cloud Migration Niterra EMEA GmbH has taken a monumental step in its digital transformation journey by partnering with Rackspace Technology. This collaboration aims to enhance operational efficiency through a swift migration to Google Cloud, capitalizing on Rackspace's extensive expertise in handling business-critical...

Continue Reading
Sweden Procures Four C-390 Millennium Aircraft from Embraer

Updated Category News Views 123

Sweden's Announcement on C-390 Millennium Acquisition In a significant development for military aviation, Sweden has officially committed to acquiring four C-390 Millennium multi-mission aircraft from Embraer. This strategic move is expected to enhance Sweden's defense capabilities and interoperability within NATO. Details of the Agreement The acquisition announcement...

Continue Reading
MindMed Initiates Phase 3 Study for MM120 in Anxiety Treatment

Updated Category News Views 332

MindMed Begins Journey with Phase 3 Study of MM120 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has crossed a significant milestone in its mission to provide breakthrough treatments for brain health disorders. The clinical-stage biopharmaceutical company has announced that the first patient is now dosed in its pivotal Phase 3 Voyage study of MM120 Orally Disintegrating...

Continue Reading
Global Office Furniture Market Set to Expand Significantly

Updated Category News Views 62

Growth Overview of the Office Furniture Market The global office furniture market is currently experiencing steady growth, fueled by the rising popularity of flexible and hybrid work environments. This shift is creating a strong demand for adaptable and ergonomic furniture that works well in both home and office contexts. As businesses evolve and expand, there’s an...

Continue Reading
Understanding Fiscal Dominance and Its Impact on Bond Markets

Updated Category News Views 467

Understanding Fiscal Dominance and Its Effects Fiscal dominance is an increasingly important concept in today's economic discussions, especially for those keen on understanding market dynamics. This economic principle involves a scenario where ongoing primary fiscal deficits stimulate nominal growth while the Central Bank maintains a loose monetary policy, failing to...

Continue Reading